Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A Cost-Utility Analysis

Prostate cancer is the most common men cancer in France. Continuous progress in oncology led to develop robot-assisted Radical Prostatectomies (rRP) and robot-assisted stereotactic body radiotherapy (rSBRT). The present study aims at comparing economic and clinical impacts of prostate cancer treatme...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 834023
Main Authors Farah, Line, Magne, Nicolas, Martelli, Nicolas, Sotton, Sandrine, Zerbib, Marc, Borget, Isabelle, Scher, Nathaniel, Guetta, Thierry, Chargari, Cyrus, Bauduceau, Olivier, Toledano, Alain
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media 24.05.2022
Frontiers Media S.A
Subjects
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2022.834023

Cover

More Information
Summary:Prostate cancer is the most common men cancer in France. Continuous progress in oncology led to develop robot-assisted Radical Prostatectomies (rRP) and robot-assisted stereotactic body radiotherapy (rSBRT). The present study aims at comparing economic and clinical impacts of prostate cancer treatments performed either with rSBRT or rRP in France. A Markov model using TreeAge Pro software was chosen to calculate annual costs; utilities and transition probabilities of localized prostate cancer treatments. Patients were eligible for radiotherapy or surgery and the therapeutic decision was a robot-assisted intervention. Over a 10-year period, rSBRT yielded a significantly higher number of quality-adjusted life years than rRP (8.37 vs 6.85). In France, rSBRT seemed more expensive than rRP (€19,475 vs €18,968, respectively). From a societal perspective, rRP was more cost-saving (incremental cost effectiveness ratio = €332/QALY). The model was sensitive to variations of costs of the initial and recurrence state in one-way sensitivity analyses. Robot-assisted stereotactic body radiotherapy seems more cost-effective than Radical Prostatectomy in terms of QALY despite the slightly higher initial cost due to the use of radiotherapy. It would be interesting to conduct comparative quality of life studies in France over longer periods of time.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology
Edited by: Linda G. W. Kerkmeijer, Radboud University Nijmegen Medical Centre, Netherlands
Reviewed by: Michael Charles Repka, University of North Carolina at Chapel Hill, United States; Sophia C. Kamran, Massachusetts General Hospital Cancer Center, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.834023